IBRX Quote, Financials, Valuation and Earnings

Exelixis has a net margin of -1404.01% compared to ImmunityBio's net margin of 21.87%. ImmunityBio's return on equity of -- beat Exelixis's return on equity of 20.97%.

ImmunityBio has a consensus price target of $14.25, signalling upside risk potential of 407.12%. On the other hand Exelixis has an analysts' consensus of $33.56 which suggests that it could fall by -1.2%. Given that ImmunityBio has higher upside potential than Exelixis, analysts believe ImmunityBio is more attractive than Exelixis.

ImmunityBio has a beta of 0.741, which suggesting that the stock is 25.865% less volatile than S&P 500. In comparison Exelixis has a beta of 0.534, suggesting its less volatile than the S&P 500 by 46.575%.

ImmunityBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exelixis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmunityBio pays -- of its earnings as a dividend. Exelixis pays out -- of its earnings as a dividend.

ImmunityBio quarterly revenues are $6.1M, which are smaller than Exelixis quarterly revenues of $539.5M. ImmunityBio's net income of -$85.7M is lower than Exelixis's net income of $118M. Notably, ImmunityBio's price-to-earnings ratio is -- while Exelixis's PE ratio is 21.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmunityBio is 261.31x versus 4.91x for Exelixis. Usually stocks with elevated PS ratios are considered overvalued.

HCA Healthcare has a net margin of -1404.01% compared to ImmunityBio's net margin of 7.26%. ImmunityBio's return on equity of -- beat HCA Healthcare's return on equity of 616.06%.

ImmunityBio has a consensus price target of $14.25, signalling upside risk potential of 407.12%. On the other hand HCA Healthcare has an analysts' consensus of $398.84 which suggests that it could grow by 34.43%. Given that ImmunityBio has higher upside potential than HCA Healthcare, analysts believe ImmunityBio is more attractive than HCA Healthcare.

ImmunityBio has a beta of 0.741, which suggesting that the stock is 25.865% less volatile than S&P 500. In comparison HCA Healthcare has a beta of 1.639, suggesting its more volatile than the S&P 500 by 63.908%.

ImmunityBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. HCA Healthcare offers a yield of 0.89% to investors and pays a quarterly dividend of $0.66 per share. ImmunityBio pays -- of its earnings as a dividend. HCA Healthcare pays out 12.61% of its earnings as a dividend. HCA Healthcare's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ImmunityBio quarterly revenues are $6.1M, which are smaller than HCA Healthcare quarterly revenues of $17.5B. ImmunityBio's net income of -$85.7M is lower than HCA Healthcare's net income of $1.3B. Notably, ImmunityBio's price-to-earnings ratio is -- while HCA Healthcare's PE ratio is 13.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmunityBio is 261.31x versus 1.13x for HCA Healthcare. Usually stocks with elevated PS ratios are considered overvalued.

Incyte has a net margin of -1404.01% compared to ImmunityBio's net margin of 9.36%. ImmunityBio's return on equity of -- beat Incyte's return on equity of 0.75%.

ImmunityBio has a consensus price target of $14.25, signalling upside risk potential of 407.12%. On the other hand Incyte has an analysts' consensus of $79.30 which suggests that it could grow by 14%. Given that ImmunityBio has higher upside potential than Incyte, analysts believe ImmunityBio is more attractive than Incyte.

ImmunityBio has a beta of 0.741, which suggesting that the stock is 25.865% less volatile than S&P 500. In comparison Incyte has a beta of 0.706, suggesting its less volatile than the S&P 500 by 29.419%.

ImmunityBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Incyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmunityBio pays -- of its earnings as a dividend. Incyte pays out -- of its earnings as a dividend.

ImmunityBio quarterly revenues are $6.1M, which are smaller than Incyte quarterly revenues of $1.1B. ImmunityBio's net income of -$85.7M is lower than Incyte's net income of $106.5M. Notably, ImmunityBio's price-to-earnings ratio is -- while Incyte's PE ratio is 497.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmunityBio is 261.31x versus 3.71x for Incyte. Usually stocks with elevated PS ratios are considered overvalued.

Q32 Bio has a net margin of -1404.01% compared to ImmunityBio's net margin of --. ImmunityBio's return on equity of -- beat Q32 Bio's return on equity of --.

ImmunityBio has a consensus price target of $14.25, signalling upside risk potential of 407.12%. On the other hand Q32 Bio has an analysts' consensus of -- which suggests that it could grow by 345.01%. Given that ImmunityBio has higher upside potential than Q32 Bio, analysts believe ImmunityBio is more attractive than Q32 Bio.

ImmunityBio has a beta of 0.741, which suggesting that the stock is 25.865% less volatile than S&P 500. In comparison Q32 Bio has a beta of -0.299, suggesting its less volatile than the S&P 500 by 129.889%.

ImmunityBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Q32 Bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmunityBio pays -- of its earnings as a dividend. Q32 Bio pays out -- of its earnings as a dividend.

ImmunityBio quarterly revenues are $6.1M, which are larger than Q32 Bio quarterly revenues of --. ImmunityBio's net income of -$85.7M is lower than Q32 Bio's net income of -$17.6M. Notably, ImmunityBio's price-to-earnings ratio is -- while Q32 Bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmunityBio is 261.31x versus -- for Q32 Bio. Usually stocks with elevated PS ratios are considered overvalued.